Sarossa Capital Overview
- Year Founded
-
1988
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
PIPE
- Latest Deal Amount
-
$663K
- Investors
-
7
Sarossa Capital General Information
Description
Sarossa PLC is an investment holding and management company. Its principal activity is an investment in and growth and development of businesses that present opportunities for value creation. It is mainly focused on portfolio businesses with product and service platforms targeting major international markets through customers and partners with an international profile. The company's equity interest in a potential investment may range from a minority position to 100 percent ownership.
Contact Information
Website
www.sarossaplc.comCorporate Office
- Floor 1 Liberation Station
- The Esplanade
- Saint Helier JE2 3AS
- Jersey, United Kingdom
Corporate Office
- Floor 1 Liberation Station
- The Esplanade
- Saint Helier JE2 3AS
- Jersey, United Kingdom
Sarossa Capital Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. PIPE | 08-May-2017 | $663K | Completed | Generating Revenue | ||
| 6. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 5. PIPE | 01-May-2008 | Completed | Generating Revenue | |||
| 4. PIPE | 15-Dec-2006 | Completed | Generating Revenue | |||
| 3. PIPE | 05-Dec-2005 | Completed | Generating Revenue | |||
| 2. PIPE | 22-Feb-2002 | $31.3M | $31.3M | Completed | Generating Revenue | |
| 1. IPO | 16-Dec-1999 | Completed | Generating Revenue |
Sarossa Capital Patents
Sarossa Capital Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-0604114-D0 | Combinations for the treatment of cancer | Inactive | 02-Mar-2006 | ||
| GB-0519397-D0 | Biological materials and uses thereof | Inactive | 23-Sep-2005 | ||
| GB-0519398-D0 | Biological materials and uses thereof | Inactive | 23-Sep-2005 | ||
| WO-2007034210-A2 | Deglycosylated anti-muc-1 antibodies and uses thereof | Inactive | 23-Sep-2005 | ||
| WO-2007034210-A3 | Deglycosylated anti-muc-1 antibodies and uses thereof | Inactive | 23-Sep-2005 | C07K16/3092 |
Sarossa Capital Signals
Sarossa Capital Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blake Holdings | Holding Company | Minority | ||
| CDIB BioScience Venture Management | Venture Capital | Minority | ||
| Joe W. and Dorothy Dorsett Brown Foundation | Impact Investing | Minority | ||
| Minerva Ventures | Corporation | Minority | ||
| Still River Fund | Venture Capital | Minority |
Sarossa Capital Acquisitions (1)
Sarossa Capital’s most recent deal was a Merger/Acquisition with Xanthus Pharmaceuticals for . The deal was made on 11-Jun-2008.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xanthus Pharmaceuticals | 11-Jun-2008 | Merger/Acquisition | Drug Discovery |
Sarossa Capital FAQs
-
When was Sarossa Capital founded?
Sarossa Capital was founded in 1988.
-
Where is Sarossa Capital headquartered?
Sarossa Capital is headquartered in Saint Helier, United Kingdom.
-
What is the size of Sarossa Capital?
Sarossa Capital has 1 total employees.
-
What industry is Sarossa Capital in?
Sarossa Capital’s primary industry is Asset Management.
-
Is Sarossa Capital a private or public company?
Sarossa Capital is a Private company.
-
What is Sarossa Capital’s current revenue?
The current revenue for Sarossa Capital is .
-
How much funding has Sarossa Capital raised over time?
Sarossa Capital has raised $136M.
-
Who are Sarossa Capital’s investors?
Blake Holdings, CDIB BioScience Venture Management, Joe W. and Dorothy Dorsett Brown Foundation, Minerva Ventures, and Still River Fund are 5 of 7 investors who have invested in Sarossa Capital.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process